OrSense

OrSense is a privately-held medical device company founded in 2004, headquartered in San Francisco with significant operations in Israel. It has developed and commercialized the NBM 200, the first non-invasive hemoglobin monitor cleared by the FDA's CBER for use in US blood banks, utilizing its proprietary SpectOLight™ technology. The company's products aim to improve patient/donor comfort, reduce waste, and streamline workflows in clinical and blood donation settings. With a strong IP portfolio of over 51 granted patents, OrSense is positioned in the growing market for point-of-care and non-invasive diagnostics.

Occlusion Spectroscopy (SpectOLight™) for non-invasive measurement of blood analytes via a finger-based sensor.

Competes against established invasive hemoglobin lab tests and point-of-care devices (e.g., HemoCue). In non-invasive monitoring, it faces competition from other emerging optical technologies and large medtech companies (like Masimo) exploring non-invasive hemoglobin, though OrSense's specific occlusion method and FDA CBER clearance for blood banks provide differentiation.